480
Participants
Start Date
October 31, 2007
Primary Completion Date
November 30, 2008
Study Completion Date
December 31, 2008
Placebo
Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
Brivaracetam
Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
Graz
Innsbrick
Linz
Vienna
Bruges
Godinne
Leuven
Montignies-sur-Sambre
Beroun
Brno
Ostrava Trebovice
Prague
Zlín
Berlin
Bernau
Bielefeld
Erlangen
Göttingen
Jena
München
Hong Kong
Bangalore
Hyderabad
Mumbai
New Delhi
Pune Maharashtra
Tirupati
Bari
Milan
Pavia
Roma
Siena
Bergen
Fredrikstad
Oslo
Sandvika
Trondheim
Kazan'
Moscow
Saint Petersburg
Samara
Yaroslavi
Singapore
Cape Town
George
Johannesburg
Tygeberg
Gwangju
Seoul
Gothenburg
Stockholm
Umeå
Taichung
Tainan City
Taoyuan Hsien
Donetsk
Kharkiv
Kyiv
Lviv
Odesa
Uzhhorod
UCB Pharma SA
INDUSTRY